A recently published study evaluated the effects of age and the site of neuromuscular monitoring on reversal of a rocuronium block using sugammadex. Block depth was titrated to a first twitch of 10 percent at the corrugator supercilii while simultaneous neuromuscular monitoring occurred at the adductor pollicis. Based on the results of this study, which of the following is most likely true?
Sugammadex is a unique compound designed as a reversal agent of rocuronium and other steroidal neuromuscular blocking agents. Sugammadex exerts its effect by forming tight complexes with contemporary steroidal neuromuscular blocking drugs (e.g., rocuronium, vecuronium). Sugammadex was recently approved by the U.S. Food and Drug Administration for use in adults for reversal of neuromuscular blockade (NMB) induced by rocuronium and vecuronium only.
Currently, 2 mg/kg of patient body weight is the recommended dose of sugammadex for reversal of NMB when the second twitch (T2) in train-of-four (TOF) stimulation...